Our Research

Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.


Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.


Our Annual Report

You can find our most recent annual report here: 2020 HMAI Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>


Researchers Identify Protein To Aid With Glioblastomas

Molecular Analysis Slide

In a recent study published in Nature Communications, Houston Methodist researchers, led by Kyuson Yun, PhDassociate professor of neurology, conducted a molecular analysis that identified a protein, S100A4, which could be a therapeutic target for restoring anti-tumor action of immune cells toward glioblastomas that have beguiled the immune system into protecting it.  Learn more>

Center for RNA Therapeutics Awarded Inno Fire Award

Inno Fire Awards Logo

The Center for RNA Therapeutics won the 2022 Houston Inno Fire Award from the Houston Business Journal for innovation in health care and life sciences. Learn more>


Latest News

Wednesday, June 1, 2022 Dr. Jun Li appointed chair of neurology department at Houston Methodist Neurological Institute
Dr. Jun Li, widely respected physician-scientist and former chair of neurology at Wayne State University, was named chair of the Stanley H. Appel Department of Neurology at the Houston Methodist Neurological Institute.   Li succeeds Dr. Stanley H. Appel, his friend and co-member in the Muscular Dyst...
Read more
Wednesday, May 11, 2022 Houston Methodist study finds clues about concussions from the gut
A recently published study by Houston Methodist scientists suggests telltale signs of concussions might be found in the gut. By taking blood, stool and saliva samples from 33 Rice University football players, the researchers were able to examine the diagnostic potential of the gut’s microbiome. They...
Read more
Thursday, April 21, 2022 Study reveals how omicron variants escape immune system to become so contagious
A new study out this week from Houston Methodist explains clever ways the BA.1 and BA.2 omicron variants escape antibodies, contributing to the ability of these variants to spread rapidly and to be so successful in infecting people with the COVID-19 virus.   The findings of this study are described...
Read more